Inhalable IL-10 as an Aerosolized Therapeutic Approach to Acute Lung Injury in Mice
Background: Acute lung injury (ALI) is a severe inflammatory condition with substantial morbidity and mortality, with no approved pharmacologic therapies targeting its underlying inflammatory pathways. Prior studies demonstrated that intratracheal interleukin (IL)−10 reduces lipopolysaccharide (LPS)- and organic dust-induced lung and systemic inflammation. Methods: The present study evaluated the aerosol performance and efficacy of nebulized IL-10 against a high-dose LPS-induced ALI model with comparisons to shock-dose dexamethasone (5 mg/kg, intraperitoneal injections). C57BL/6 male mice were challenged with LPS (5 mg/mL) and treated with low- (0.1 mg/mL), mid- (0.5 mg/mL), or high-dose (1 mg/mL) IL-10, or vehicle, all by nose-only aerosol inhalation (15-minute exposure duration), with euthanasia on day 2. Results: Aerosolized IL-10 exhibited a mass median aerodynamic diameter of 1.66 µm (geometric standard deviation 2.04). Pulmonary deposited doses were 5.5–5.7 µg/mouse for LPS and 10.4, 21.3, and 38.4 (ug/kg) for low-, mid-, and high-dose IL-10. LPS-induced weight loss (18.6%) was reduced by high IL-10 (8.4%) and dexamethasone (7.0%), with no significant difference between treatments. Increased lung weights (40.8%) following LPS challenge were significantly reduced by mid- and high-dose IL-10 and dexamethasone. LPS-induced airway total cell and neutrophil counts in bronchoalveolar lavage fluid were not reduced by either treatment. In contrast, IL-10 treatment produced dose-dependent reductions in LPS-induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ, KC/CXCL1, MCP-1, and MIP-1α), with beneficial responses at the high IL-10 dose comparable to dexamethasone. Histopathology demonstrated dose-responsive reductions in LPS-induced peribronchovascular mixed cellular lung inflammation, significant at mid- and high IL-10 doses and comparable to dexamethasone. Conclusion: Overall, aerosolized IL-10 demonstrated aerodynamic properties consistent with deep lung penetration and dose-dependent efficacy at ≥21.3 µg/kg, achieving anti-inflammatory effects comparable with dexamethasone in this ALI murine model.
Authors
- Samuel A. Vance (ORCID: https://orcid.org/0000-0001-7604-0218)
- Todd A. Wyatt (ORCID: https://orcid.org/0000-0002-9273-6730)
- Jill A. Poole (ORCID: https://orcid.org/0000-0002-6236-2563)
- Jason M. Cox (ORCID: https://orcid.org/0000-0002-1919-7996)
- Steven M. Dudek (ORCID: https://orcid.org/0000-0001-5624-0714)
- Edward G. Barrett (ORCID: https://orcid.org/0000-0003-0521-0683)
- Amy J. Nelson
Institutions
- University of Illinois Chicago (US)
- University of Chicago (US)
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1177/19412711261507383
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00